Dianthus Therapeutics, Inc. (DNTH) — Stock Score Summary

Dianthus Therapeutics, Inc. (DNTH) has a MoatMap StockRank of 60/100 based on Quality (38/100), Value (36/100), and Momentum (70/100) factor scores. The current signal is HOLD. Dianthus is an early-stage clinical biotech company with no revenues or owner earnings, representing a speculative profile that violates our core quality and margin of safety principles.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation complement inhibitors designed to treat severe and rare autoimmune diseases. The company's competitive moat is rooted in its novel scientific approach to complement system biology and proprietary antibody drug candidates engineered for enhanced potency and prolonged half-life. Dianthus aims to address significant unmet medical needs within underserved autoimmune conditions, representing a high-potential player in targeted immunology.

Key Financial Metrics

Price$84.97
Market Cap$5.0B
P/E (Forward)-18.67
Price/Book3.94
Return on Equity-22.7%
Return on Invested Capital-35.6%
Debt/Equity0.11
Gross Margin100.0%
Operating Margin-10050.3%
Revenue Growth-60.2%
Free Cash Flow$-71M

Dianthus Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Dianthus Therapeutics, Inc.’s (DNTH) StockRank?
MoatMap’s StockRank for Dianthus Therapeutics, Inc. (DNTH) is 60/100, with a Hold signal. It is a composite of Quality (38), Value (36), and Momentum (70) factor ranks across MoatMap’s 19,000+ stock universe.
Does Dianthus Therapeutics, Inc. have an economic moat?
Dianthus Therapeutics, Inc. (DNTH) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Dianthus Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Dianthus Therapeutics, Inc. (DNTH) is Hold, based on a StockRank of 60/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Dianthus Therapeutics, Inc. in?
Dianthus Therapeutics, Inc. (DNTH) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksDNTH deep dive reportAI ChampionsHow we score stocksSense-check another stock